We determined the abilities of 10 technologies to detect and quantify a common drug-resistant mutant of human immunodeficiency virus type 1 (lysine to asparagine at codon 103 of the reverse transcriptase) using a blinded test panel containing mutant-wild-type mixtures ranging from 0.01% to 100% mutant. Two technologies, allele-specific reverse transcriptase PCR and a Ty1HRT yeast system, could quantify the mutant down to 0.1 to 0.4%. These technologies should help define the impact of low-frequency drug-resistant mutants on response to antiretroviral therapy.
The high replication rate and error-prone reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1) generates a large population of genetically distinct variants (1) . Variants with a fitness advantage can rapidly outcompete others (1) . In the case of antiretroviral therapy, outgrowth of drug-resistant mutants can lead to treatment failure (7) . After the removal of drug selection, resistant mutants often decline to undetectable levels, albeit at variable rates (2, 6) . These "undetectable" mutants can rapidly reappear after reinitiation of antiretroviral therapy, but it is uncertain how often they cause treatment failure (3, 8, 12) . Answering this question requires methods to accurately detect drug-resistant mutants present at a low frequency.
Standard genotyping methods provide a composite of the HIV sequences present, but they generally do not detect mutants that comprise less than 20% of the virus population (11, 18) . Several assays have been developed with improved sensitivity for resistant mutants (4, 10, (13) (14) (15) (16) (17) 20) ; however, their relative performances have not been assessed. In the current study, a panel of wild-type-mutant HIV-1 mixtures was created to evaluate the performance of these assays. The mutant virus encodes the K103N mutation in HIV-1 RT that is commonly selected for by nonnucleoside RT inhibitor (NNRTI) therapy and confers cross-resistance to all FDA-approved NNRTIs. Viral stocks were generated by CaPO 4 transfection of 293T cells (9) with the infectious plasmid clones of HIV-1 LAI encoding wild-type 103K (AAA) or mutant 103N (AAC) RT (19) . The HIV-1 RNA concentrations of stocks were determined (Amplicor HIV-1 Monitor Assay version 1.0; Roche Molecular Systems, Branchburg, NJ). Viral mixtures were generated by adding appropriate amounts of mutant and wild-type virus stocks, as determined by the HIV-1 RNA concentration, to yield final mutant fractions of 0, 0.01, 0.1, 0.4, 1, 2, 5, 10, 25, 50, and 100%. Each of the viral mixtures was then spiked into 25 ml of HIV-seronegative human plasma from a single donor to obtain a final HIV-1 RNA concentration of ϳ1 ϫ 10 6 RNA copies/ml. The mean (Ϯ standard deviation) HIV-1 RNA in the mixtures was 5.4 ϫ 10 5 Ϯ 9.2 ϫ 10 4 copies/ml (each mixture was tested in triplicate), which is within twofold of the expected concentration.
A broad solicitation of interest in testing the panel was sent to academic, government, and industry laboratories working on the detection of minor drug-resistant variants. Thirteen laboratories were selected with the goal of maximizing the number of technologies evaluated. The technologies included pyrosequencing of PCR products (15) , real-time allele-specific RT-PCR (ASPCR) (10, 13, 17) , oligonucleotide ligation-based assays (OLA) (4), a Ty1/HIV-1 RT hybrid system (TyHRT) (14) , single-genome sequencing (SGS) (16) , and a line probe assay (LiPA) (VERSANT HIV-RT Resistance Assay; Bayer, Berkley, CA) (20) . Standard genotyping methods using FDAcleared kits were included (HIV-1 TRUGENE [Bayer, Tarrytown, NY] and ViroSeq v2.0 [Celera Diagnostics, Alameda, CA]). In one laboratory, the RT-PCR product from the ViroSeq method was cloned (Topo Cloning; InVitrogen, Carlsbad, CA) and sequenced using the Big Dye Terminator kit (Applied Biosystems, Foster City, CA).
The nine viral mixtures (a 1.0-ml aliquot each) and two controls (100% mutant and 0% mutant) were distributed as a blinded test panel to participating laboratories. The panels were tested once because of their large size and limited supply. All results were reported on a standardized form, submitted electronically. The detection limit of an assay was defined as the lowest percent mutant detected by the assay, provided all higher-mutant fractions were detected and that the 0% mutant control was reported as negative. The quantification limit of an assay was defined as the lowest percent mutant detected, provided that all higher-mutant samples were ordered correctly. Table 1 shows the relative performances of the methods.
Of the technologies evaluated, two out of three ASPCR methods (13, 17) and the TyHRT (14) assay were the most sensitive, quantifying the mutant to 0.1 to 0.4% (Table 1) . This is 10-to 100-fold more sensitive than standard HIV-1-genotyping methods. The third ASPCR method (10) was less sensitive, which may be attributable to differences in primer design or the amount of sample analyzed.
Despite the high sensitivity of ASPCR, it is limited by singleallele analysis and false negatives from nucleotide polymorphisms that can destabilize primer binding (6) . An advantage of using TyHRT is the ability to directly confirm the mutant allele by sequencing individual yeast clones and/or to identify novel NNRTI resistance mutations (reference 14 and data not shown). A shortcoming of the TyHRT assay is that resistance to nucleoside analogs and protease inhibitors cannot be assessed.
Pyrosequencing and SGS (45 sequences/mixture) had intermediate detection limits of 2% mutant (Table 1 ) but were not quantitative below 10% 103N. SGS has the advantage of analyzing mutation linkages without the need for cloning (16) , but a high sensitivity for minor variants requires the sequencing of many genomes, e.g., 490 single genomes to detect a mutant at a 1% frequency with 99% certainty, which is currently impractical.
The TRUGENE and ViroSeq v2.0 genotyping methods quantified the 103N mutant at frequencies of 5 and 10%, respectively. The sensitivities of these products are higher than previously reported for population-based sequencing (11) , which may be attributable to scrutiny of the 103 codon by the laboratories and a low background of plasmid-derived recombinant viruses. Results with other mutants may differ, and more importantly, neither method was developed or cleared for minor-variant detection.
Cloning and sequencing of RT-PCR products from a single or multiple cDNA reactions (ViroSeq) did not improve quantification of mutants over that of the standard commercial assays (11) . This result was not unexpected, since only 25 clones per reaction were sequenced. Sensitivity could be improved by increasing the number of clones analyzed, but the labor and cost involved are prohibitive.
The OLA (4) and LiPA (20) assays (LiPA was used here with LiPAScan, an automated strip reader) detected the 103N mutant at frequencies between 2 and 10% (Table 1) . One (Table 1) . Other comparative studies of genotypic assays for HIV-1 mutant detection have been performed (4, 5, 11, 15) , but none has covered the breadth of technologies evaluated here. Additional panels of virus mixtures and clinical samples need to be tested to assess the potential impacts of different codons, viral heterogeneity, and operator experience on assay performance, as has been noted previously (6, 18) . Nevertheless, our findings indicate that several assays are available to study the emergence, decay, and therapeutic significance of minor populations of drug-resistant HIV-1.
